TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07881120: A 2-Stage Operationally Seamless Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Afimetoran in Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy

Sponsor: Beeline Medicines Corporation · Phase: PHASE2/PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 390 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$13,468,800

Rescue Site Savings

+$8,880,990

Unlock Full NCT07881120 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07881120 Rescue Dossier →